The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 06, 2022

Filed:

Jan. 28, 2019
Applicant:

Hyesook Kim, Bloomfield Hills, MI (US);

Inventor:

Hyesook Kim, Bloomfield Hills, MI (US);

Assignee:

Detroit R&D, Inc., Bloomfield Hills, MI (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/92 (2006.01); G01N 33/68 (2006.01); G01N 33/573 (2006.01);
U.S. Cl.
CPC ...
G01N 33/92 (2013.01); G01N 33/573 (2013.01); G01N 33/6887 (2013.01); G01N 2405/00 (2013.01); G01N 2560/00 (2013.01); G01N 2800/32 (2013.01); G01N 2800/42 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.


Find Patent Forward Citations

Loading…